STEP UP: High-dose semaglutide led to 21% weight loss for adults with obesity
Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than adults receiving semaglutide 2.4 mg, according to top-line results from the STEP UP phase 3b trial. The trial enrolled 1,407 adults with a BMI of 30 kg/m2 or higher and without diabetes. Participants were randomly assigned to once-weekly semaglutide 7.2 mg, once-weekly